Millennium Biotechnologies Group, Inc. 

(Public, OTC:MBTG)   Watch this stock   
Find more results for MBTG

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -112.04% -761.53%
Operating margin -54.26% -406.77%
EBITD margin - -406.57%
Return on average assets -386.47% -1466.07%
Return on average equity - -
Employees 6 -

Address

665 Martinsville Road Suite 219
Basking Ridge, NJ 07920
United States - Map
+1-908-6042500 (Phone)

Website links

Millennium Biotechnologies Group, Inc. discussions

  View all discussions »

Description

Millennium Biotechnologies Group, Inc. (Millennium) is engages in the research, development and marketing of specialized nutritional supplements as an adjunct to medical treatments for select medical conditions, as well as for athletes. The Company’s marketed products are targeted toward immuno-compromised individuals undergoing medical treatment for diseases, such as cancer, as well as individuals living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and wound healing and post-surgical healing and geriatric among other conditions. Millennium also is marketing the Surgex product line to elite athletes. Millennium’s manufactures and markets five product lines and 21 stock keeping units (SKU’s) to seven separate target markets.

Officers and directors

Mark C. Mirken
Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer
Age: 64
Frank Guarino
Chief Financial Officer
Age: 34
Benjamin Custodio
Executive Vice President - International Sales, Director
Age: 66
Carl Germano
Executive Vice President - Research and Product Development
Age: 54
Michael C. James
Director
Age: 50